Müge Kopuz Álvarez Noval
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Müge Kopuz Álvarez Noval has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Luay Şerifoğlu
Department of Neurosurgery, Ümraniye Training and Research Hospital, Istanbul, Turkey
2 shared publications - Seda Gulec Yilmaz
Department of Medical Biology, Faculty of Medicine, Yeditepe University, Istanbul, Turkey
2 shared publications - Selvi Duman Bakirezer
Department of Basic Medical Sciences, Faculty of Medicine, Yeditepe University, Istanbul 34755, Türkiye
2 shared publications - Selçuk Özdoğan
Department of Neurosurgery, Istanbul Training and Research Hospital, Istanbul, Turkey
2 shared publications - Alev Cumbul
Department of Histology and Embryology, Faculty of Medicine, Yeditepe University, İstanbul 34758, Türkiye
1 shared publication - Ali Haluk Duzkalir
Department of Neurosurgery, Koç University School of Medicine, Istanbul, Turkey
1 shared publication
Latest Publications
- Open Access
- 15 January 2026
- Published by Springer Nature in Neurosurgical Review
- Vol. 49 (1) , 126
Regulatory function of HSA-miR-186-5p on interleukin-2 expression in lumbar degenerative disc disease: a case-control study and subgroups analysis
Lumbar degenerative disc disease (LDDD) is characterized by persistent inflammation and extracellular matrix degradation. Emerging as main controllers in its pathogenesis are microRNAs (miRNAs) and proinflammatory cytokines. Through the JAK/STAT signalling pathway, HSA-miR-186-5p has been linked to modulating cytokine expression, including interleukin-2 (IL-2). The aim is to find the expression levels of IL-2 and HSA-miR-186-5p in LDDDpatients and investigate their possible correlation with disease degree. 110 LDDD patients and 17 healthy controls wereincluded. ELISA measured serum IL-2 concentrations, and RT-qPCRestimated miR-186-5p levels. The Oswestry Disability Index (ODI) guidedpatients into five subgroups (G1–G5). One-way ANOVA and correlationanalysis were applied in statistical comparisons. LDDD patients had notably higher IL-2 levels than controls ( p p < 0.001), with G1and G5 having the lowest levels found. Across groups, an inverse trend in IL-2 and miR-186-5p expression was noted. Results imply a dysregulated interaction between HSA-miR-186-5p and IL-2 in LDDD. Particularly in early and moderate stages ofdisease, miR-186-5p downregulation could help to explain increased IL-2-mediated inflammation. These biomarkers could provide information ondisease activity and present targets for new treatments.
- 15 January 2026
- Published by Springer Nature in Neurosurgical Review
- Vol. 49 (1) , 126
Open AccessRegulatory function of HSA-miR-186-5p on interleukin-2 expression in lumbar degenerative disc disease: a case-control study and subgroups analysis
Lumbar degenerative disc disease (LDDD) is characterized by persistent inflammation and extracellular matrix degradation. Emerging as main controllers in its pathogenesis are microRNAs (miRNAs) and proinflammatory cytokines. Through the JAK/STAT signalling pathway, HSA-miR-186-5p has been linked to modulating cytokine expression, including interleukin-2 (IL-2). The aim is to find the expression levels of IL-2 and HSA-miR-186-5p in LDDDpatients and investigate their possible correlation with disease degree. 110 LDDD patients and 17 healthy controls wereincluded. ELISA measured serum IL-2 concentrations, and RT-qPCRestimated miR-186-5p levels. The Oswestry Disability Index (ODI) guidedpatients into five subgroups (G1–G5). One-way ANOVA and correlationanalysis were applied in statistical comparisons. LDDD patients had notably higher IL-2 levels than controls ( p p < 0.001), with G1and G5 having the lowest levels found. Across groups, an inverse trend in IL-2 and miR-186-5p expression was noted. Results imply a dysregulated interaction between HSA-miR-186-5p and IL-2 in LDDD. Particularly in early and moderate stages ofdisease, miR-186-5p downregulation could help to explain increased IL-2-mediated inflammation. These biomarkers could provide information ondisease activity and present targets for new treatments.
- Open Access
- 6 March 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (5) , 1772
Investigation of MicroRNA-17 Expression, Tumor Necrosis Factor-α, and Interleukin-6 Levels in Lumbar Degenerative Disc Disease: Case–Control Study
Background/Objectives: The aim of the study is to investigate the role of microRNA-17 (miRNA-17), tumor necrosis factor-alpha (TNF-α), and interleukin-6 (IL-6) in the pathogenesis of lumbar degenerative disc disease (LDDD). The goal is to explore how miRNA-17 regulates inflammation and apoptosis within the intervertebral discs, with a particular focus on its involvement in inflammatory pathways via NF-κB signaling. This research seeks to uncover the molecular mechanisms that contribute to LDDD and its associated chronic lower back pain and disability. Methods: A case–control study was conducted, involving 110 patients diagnosed with LDDD and 17 healthy control individuals. Serum levels of miRNA-17, TNF-α, and IL-6 were measured using quantitative real-time PCR and enzyme-linked immunosorbent assays (ELISAs). The patients were further categorized based on the severity of their condition using the Oswestry Disability Index (ODI), which classified them into five subgroups. The correlation between miRNA-17 expression, pro-inflammatory cytokines, and disease severity was analyzed statistically. Results: The results demonstrated a significant downregulation of microRNA-17 in patients with LDDD compared to healthy controls. Inflammatory markers TNF-α and IL-6 were found to be significantly elevated in the patient group. A peak in inflammation and miRNA-17 expression was observed in patients with moderate to severe disability (ODI Grade 3), while inflammation levels decreased in more advanced stages of the disease (ODI Grades 4 and 5), suggesting a possible shift in disease dynamics. Conclusions: This study demonstrates that miRNA-17 plays a regulatory role in inflammation during the progression of LDDD, particularly through the modulation of TNF-α and IL-6 levels. The findings indicate that inflammation is most pronounced in the mid-stages of LDDD, while the later stages are characterized by structural damage rather than ongoing inflammation. These insights could help guide future therapeutic strategies aimed at targeting the molecular mechanisms underlying LDDD, potentially improving patient outcomes.
- 6 March 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (5) , 1772
Open AccessInvestigation of MicroRNA-17 Expression, Tumor Necrosis Factor-α, and Interleukin-6 Levels in Lumbar Degenerative Disc Disease: Case–Control Study
Background/Objectives: The aim of the study is to investigate the role of microRNA-17 (miRNA-17), tumor necrosis factor-alpha (TNF-α), and interleukin-6 (IL-6) in the pathogenesis of lumbar degenerative disc disease (LDDD). The goal is to explore how miRNA-17 regulates inflammation and apoptosis within the intervertebral discs, with a particular focus on its involvement in inflammatory pathways via NF-κB signaling. This research seeks to uncover the molecular mechanisms that contribute to LDDD and its associated chronic lower back pain and disability. Methods: A case–control study was conducted, involving 110 patients diagnosed with LDDD and 17 healthy control individuals. Serum levels of miRNA-17, TNF-α, and IL-6 were measured using quantitative real-time PCR and enzyme-linked immunosorbent assays (ELISAs). The patients were further categorized based on the severity of their condition using the Oswestry Disability Index (ODI), which classified them into five subgroups. The correlation between miRNA-17 expression, pro-inflammatory cytokines, and disease severity was analyzed statistically. Results: The results demonstrated a significant downregulation of microRNA-17 in patients with LDDD compared to healthy controls. Inflammatory markers TNF-α and IL-6 were found to be significantly elevated in the patient group. A peak in inflammation and miRNA-17 expression was observed in patients with moderate to severe disability (ODI Grade 3), while inflammation levels decreased in more advanced stages of the disease (ODI Grades 4 and 5), suggesting a possible shift in disease dynamics. Conclusions: This study demonstrates that miRNA-17 plays a regulatory role in inflammation during the progression of LDDD, particularly through the modulation of TNF-α and IL-6 levels. The findings indicate that inflammation is most pronounced in the mid-stages of LDDD, while the later stages are characterized by structural damage rather than ongoing inflammation. These insights could help guide future therapeutic strategies aimed at targeting the molecular mechanisms underlying LDDD, potentially improving patient outcomes.
- 10 April 2024
- Published by Elsevier in Prostaglandins & Other Lipid Mediators
- Vol. 173, 106837
Pomegranate seed oil alleviates colitis: Therapeutic effects achieved by modulation of oxidative stress and inflammation in a rat model
- 10 April 2024
- Published by Elsevier in Prostaglandins & Other Lipid Mediators
- Vol. 173, 106837
Pomegranate seed oil alleviates colitis: Therapeutic effects achieved by modulation of oxidative stress and inflammation in a rat model